Exact Sciences Corporation (NASDAQ:EXAS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]
Exact Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients [Yahoo! Finance]
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $90.00 to $85.00. They now have a "buy" rating on the stock.
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at BTIG Research from $85.00 to $80.00. They now have a "buy" rating on the stock.